Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions
IntroductionAntibody-drug conjugates (ADCs) have emerged as a transformative therapeutic modality in oncology, offering unprecedented precision in targeting tumor cells while sparing healthy tissues. In bladder cancer, a malignancy with high recurrence…